Metreleptin treatment was also associated with lowering of serum triglyceride concentration in aggregated lipodystrophy, in generalized and partial subgroups, and in those with LMNA, PPARG, AGPAT2 and BSCL2 mutations (92 to 1760 mg/dL least square mean reduction for analyses of untransformed data) (Level 3 evidence, Supplementary Data 3, Fig. 2). This evidence concerns the gene BSCL2 and lipodystrophy.